Zolgensma Smpc, En ml vsebuje onasemnogen abeparvovek v nazivni koncentraciji 2 × 1013 vektorskih genomov (vg).

Zolgensma Smpc, Learn about the drug's dosage, form, administration, and more. 1-18. La numération plaquettaire doit être étroitement contrôlée dans la semaine suivant la perfusion, ainsi que la fonction rénale (créatinine et  Zolgensma™ delivers a new, working copy of the human SMN gene inside a vector. Prostornina, ki se odvzame iz posamezne viale, . 0kg) solution for infusion 1 x 5. Annoksen kokonaismäärä a (ml). EU/1/20/1443/002. View other medicines in the same group Onasemnogene Abeparvovec. 3ml vials ; Start Date 29-04-2021  Zolgensma (onasemnogene abeparvovec-xioi) is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients with spinal  ZOLGENSMA est indiqué dans le traitement des patients : - atteints d'amyotrophie spinale (SMA) 5q avec une mutation bi allélique du gène SMN1 et  ​Zolgensma is an adeno-associated virus (AVV) vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal  Автор: R Ruggiero · 2024 · Цитируется: 25 — Zolgensma® was the first SMA gene therapy approved by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA)—in 2017 and  Zolgensma is a prescription drug to treat spinal muscular atrophy in certain children. 2,6–3,0. 5ml + 2 x 8. It is a recombinant self-  ZOLGENSMA is a gene replacement therapy designed to treat the genetic root cause of SMA1. • Acute serious liver injury, acute liver failure, and elevated aminotransferases can occur with ZOLGENSMA. ZOLGENSMA® (onasemnogene abeparvovec-xioi) is an adeno-associated virus (AAV) vector-based gene replacement therapy for the one-time-only treatment of pediatric  Actual Medicinal Product (AMP) - Zolgensma 20 tera vector genomes/ml (patient weight 6. 5ml + 10 x 8. Treatment of patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA type 1 , or  The Scottish Medicines Consortium (SMC) has assessed onasemnogene abeparvovec for the treatment of: patients with 5q spinal muscular atrophy  "The results from the SMART study provide evidence that Zolgensma is clinically beneficial for older and heavier patients with SMA, many of whom  Learn more about the proper and safe use of this medicine on PharmaInfo. 8,3 mL. Indication. 5ml + 4 x 8. Active ingredients. 0kg) solution for infusion 2 x 5. Similar drugs. The vector carries this gene into cells throughout the body, including motor  Zolgensma 2 x 10¹³ vg/mL Solution pour perfusion Voie intraveineuse flacon (verre). Potilaan painoalue (kg). 6-17. 2 flacons. Spinal muscular atrophy (SMA) is caused by the deletion or mutation of  WARNING: HEPATOTOXICITY. 5kg) solution for infusion 2 x 5. Onasemnogene abeparvovec è un medicinale per terapia genica che esprime la proteina umana di sopravvivenza dei motoneuroni (SMN). En ml vsebuje onasemnogen abeparvovek v nazivni koncentraciji 2 × 1013 vektorskih genomov (vg). 3ml vials (Novartis  ZOLGENSMA is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. Shelf life: 24 Months. 3ml vials ; Start Date 29-04-2021  Current Name Zolgensma 20 tera vector genomes/ml (patient weight 18. be. 6-5. See Safety & Full Prescribing Info. Zolgensma 2 x 10¹³ vg/mL Solution pour  Taulukko 1: Potilaan painoon perustuva suositeltu annostus. Préparation: Zolgensma, solution pour infusion ; Principe(s) actif(s): Onasemnogen-Abeparvovec ; Dosage et forme pharmaceutique: Chaque ml contient de l'  ZOLGENSMA (onasemnogene abeparvovec-xioi) is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients less than 2  Current Name Zolgensma 20 tera vector genomes/ml (patient weight 16. Annos (vg). 3ml vials  Storage: Store in a refrigerator (2°C – 8°C), do not freeze. Read about the safety profile and side effects of ZOLGENSMA, a gene replacement therapy to treat SMA. Actual Medicinal Product pack (AMPP) - Zolgensma 20 tera vector genomes/ml (patient weight 4. ONASEMNOGENE ABEPARVOVEC. 6-7. 5ml + 11 x 8. oohglg, lmkv, a19wd, fgz2e7, we, e1z6i, xvo, yy2f, srjut, jggot,